Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
18
×
Tags
life sciences
national blog main
national top stories
new york top stories
18
×
boston blog main
new york blog main
boston top stories
san francisco blog main
san francisco top stories
san diego blog main
san diego top stories
biotech
fda
national
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
texas blog main
drugs
boston
akcea therapeutics
alnylam pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
merck
new york
patisiran
regeneron pharmaceuticals
roche
What
medicine
18
×
drug
fda
new
approved
cancer
alnylam
bio
making
patients
roundup
announced
big
cells
ceo
depression
disease
friday
gene
genetic
goes
help
known
latest
long
medicines
nobel
oks
post
prize
rna
rnai
specifically
study
therapy
time
treatment
uses
way
week
Language
unset
Current search:
xconomy.com
×
medicine
×
photo
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Ireland to Sequence 400K Genomes With New Precision Medicine Effort
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?